Tiziana reports biomarker data linking nasal foralumab to reduced CSF inflammation and microglial PET signal in na-SPMS patients with PIRA

Reuters02-25
Tiziana reports biomarker data linking nasal foralumab to reduced CSF inflammation and microglial PET signal in na-SPMS patients with PIRA

Tiziana Life Sciences Ltd. reported new biomarker findings from an open-label expanded-access program evaluating intranasal foralumab, an anti-CD3 monoclonal antibody, in 10 patients with non-active secondary progressive multiple sclerosis with progression independent of relapse activity. The results were already presented in a late-breaking poster by investigators from Brigham and Women’s Hospital and included paired CSF proteomics and [F-18]PBR06-PET assessments showing reduced PET measures of microglial activation and proteomic shifts consistent with decreased inflammatory markers and increased neuroprotective proteins, with no serious treatment-related adverse events reported. The company also said a randomized, double-blind, placebo-controlled Phase 2a trial in na-SPMS is ongoing, with top-line data expected in the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602250700OMX_____CNEWS_EN_GNW9660999_en) on February 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment